Cell MedX Corp. (OTCQB:CMXC) announced that it had received and successfully tested its first eBalance Professional Series (Pro) device as of late 2015.

Cell MedX Corp. (OTCQB:CMXC) announced that it had received and successfully tested its first eBalance Professional Series (Pro) device as of late 2015.
According to the company’s press release:

The eBalance Pro device is designed to study targeted effects on glucose control, increased insulin sensitivity and insulin resistance, abatement of diabetic neuropathy, accelerated wound healing as well as pain management for both non-diabetic and diabetic patients.
The initial eBalance Pro device is a first generation variable sensitivity unit controlled through a computer interface employing custom software to administer the therapeutic protocols. The initial Pro device was rigorously tested by the Cell MedX team and was found to perform better than anticipated. These positive results led the Company to commission the manufacture of an additional 25 units which are scheduled to arrive in February and are anticipated to significantly accelerate ongoing research efforts.

Cell MedX President and CEO Mr. Frank McEnulty stated:

We are looking forward to getting these devices into the hands of researchers as quickly as possible. The new Pro model is faster and easier for physicians and clinical staff to employ, a factor which will help satisfy our ongoing need for quantifiable research data. We anticipate that practical use of the units will translate into potential for increased interest and future demand as we move forward towards commercialization. All in all an excellent start to the year and we wish all our shareholders and supporters great success in 2016.

Click here to view the full press release.

insulin pain Company News